WO2008109376B1 - Nucleic acid compounds for inhibiting bcr-abl gene expression and uses thereof - Google Patents

Nucleic acid compounds for inhibiting bcr-abl gene expression and uses thereof

Info

Publication number
WO2008109376B1
WO2008109376B1 PCT/US2008/055378 US2008055378W WO2008109376B1 WO 2008109376 B1 WO2008109376 B1 WO 2008109376B1 US 2008055378 W US2008055378 W US 2008055378W WO 2008109376 B1 WO2008109376 B1 WO 2008109376B1
Authority
WO
Grant status
Application
Patent type
Prior art keywords
strand
molecule
mdrna
nucleotides
och
Prior art date
Application number
PCT/US2008/055378
Other languages
French (fr)
Other versions
WO2008109376A1 (en )
Inventor
Steven C Quay
James Mcswiggen
Narendra K Vaish
Mohammad Ahmadian
Original Assignee
Mdrna Inc
Steven C Quay
James Mcswiggen
Narendra K Vaish
Mohammad Ahmadian
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • C12N2310/111Antisense spanning the whole gene, or a large part of it
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering N.A.
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/3212'-O-R Modification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/323Chemical structure of the sugar modified ring structure
    • C12N2310/3231Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/50Physical structure
    • C12N2310/53Physical structure partially self-complementary or closed

Abstract

The present disclosure provides meroduplex ribonucleic acid molecules (mdRNA) capable of decreasing or silencing BCR-ABL gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to a BCR-ABL mRNA. In addition, the meroduplex may have at least one uridine substituted with a 5-methyluridine, a nucleoside replaced with a locked nucleic acid, or optionally other modifications, and any combination thereof. Also provided are methods of decreasing expression of a BCR-ABL gene in a cell or in a subject to treat a BCR-ABL-related disease.

Claims

AMENDED CLAIMS received by the International Bureau on 22 September 2008(22.09.2008)
1. A meroduplex ribonucleic acid (mdRNA) molecule that down regulates the expression of a human Breakpoint Cluster Region- Abelson Murine Leukemia Viral Oncogene homolog (BCR-ABL) mRNA, the mdRNA molecule comprising a first strand of 15 to 40 nucleotides in length that is complementary to a nucleic acid sequence as set forth in SEQ ID NO: 1158-1178 or SEQ ID NOS: 1166- 1178, and a second strand and a third strand that is each complementary to non-overlapping regions of the first strand, wherein the second strand and third strand can anneal with the first strand to form at least two double-stranded regions spaced apart by a nick or a gap.
2. The mdRNA molecule of claim 1 wherein the first strand is 15 to 25 nucleotides in length or 26 to 40 nucleotides in length.
3. The mdRNA molecule of claim 1 wherein the gap comprises from 1 to 10 unpaired nucleotides.
4. The mdRNA molecule of claim 1 wherein the mdRNA molecule comprises at least one 5-methyluridine, 2-thioribothyrnidine, or 2'-O-methyl-5- methyluridine.
5. The mdRNA molecule of claim 1 wherein the mdRNA molecule comprises at least one locked nucleic acid (LNA) molecule, deoxy nucleotide, G clamp, 2'-sugar modification, modified internucleoside linkage, or any combination thereof.
6. The mdRNA molecule of claim 1 wherein the mdRNA contains an overhang of one to four nucleotides on at least one 3 '-end that is not part of the gap or has a blunt end at one or both ends of the mdRNA.
7. An mdRNA molecule that down regulates the expression of a human BCR-ABL mRNA, the mdRNA molecule comprising a first strand of 15 to 40 nucleotides in length that is complementary to a nucleic acid sequence as set forth in SEQ ID NO:1158-1178 or SEQ ID NOS:1166-1178, and a second strand and a third strand that is each complementary to non-overlapping regions of the first strand, wherein the second strand and third strand can anneal with the first strand to form at
AMENDED SHEET (ARTICLE 19) i least two double-stranded regions spaced apart by a nick or a gap, and wherein at least one pyrimidine of the mdRNA molecule is a pyrimidine nucleoside according to Formula I or II:
Figure imgf000004_0001
wherein:
R1 and R2 are each independently a -H, -OH, -OCH3, -OCH2OCH2CH3, -OCH2CH2OCHa, halogen, substituted or unsubstituted C1-C10 alkyl, alkoxy, alkoxyalkyl, hydroxyalkyl, carboxyalkyl, alkylsulfonylamino, aminoalkyl, dialkylamino, alkylaminoalkyl, dialkylaminoalkyl, haloalkyl, trifluoromethyl, cycloalkyl, (cycloalkyl)alkyl, substituted or unsubstituted C2-C10 alkenyl, substituted or unsubstituted -O-allyl, -0-CH2CH=CH2, -0-CH=CHCH3, substituted or unsubstituted C2-C10 alkynyl, carbamoyl, carbamyl, carboxy, carbonylamino, substituted or unsubstituted aryl, substituted or unsubstituted aralkyl, -NH2, -NO2, -C≡, or heterocyclo group,
R3 and R4 are each independently a hydroxyl, a protected hydroxyl, a phosphate, or an internucleoside linking group, and
R and R are each independently O or S.
8. The mdRNA molecule of claim 7 wherein the first strand is 15 to 25 nucleotides in length or 26 to 40 nucleotides in length.
9. The mdRNA molecule of claim 7 wherein the gap comprises from 1 to 10 unpaired nucleotides.
10. The mdRNA molecule of claim 7 wherein at least one nucleoside is according to Formula I and in which R1 is methyl and R2 is -OH or -O-methyl.
AMENDED SHEET (ARTICLE 19)
11. The mdRNA molecule of claim 7 wherein at least one R is selected from the group consisting of 2'-0-(Ci-C5) alkyl, 2'-O-methyl, 2'-OCH2OCH2CH3, 2'-OCH2CH2OCH3, 2'-0-allyl, and fluoro.
12. The mdRNA molecule of claim 7 wherein the mdRNA molecule comprises at least one 5-methyluridine, 2-thioribothymidine, or 2'-O-methyl-5- methyluridine.
13. The mdRNA molecule of claim 7 wherein the mdRNA molecule comprises at least one locked nucleic acid (LNA) molecule, deoxy nucleotide, G clamp, 2'-sugar modification, modified internucleoside linkage, or any combination thereof.
14. The mdRNA molecule of claim 7 wherein contains an overhang of one to four nucleotides on at least one 3 '-end that is not a part of the gap or the dsRNA molecule has a blunt end on one or both ends of the mdRNA molecule.
15. An mdRNA molecule that down regulates the expression of a human BCR-ABL mRNA, the mdRNA molecule comprising a first strand of 15 to 40 nucleotides in length that is complementary to a nucleic acid sequence as set forth in SEQ ID NO:1158-1178 or SEQ ID NOS:1166-1178, and a second strand and a third strand that is each complementary to non-overlapping regions of the first strand, wherein the second strand and third strand can anneal with the first strand to form at least two double-stranded regions spaced apart by a nick or a gap, and wherein the double-stranded regions have a combined length of about 15 base pairs to about
40 base pairs.
16. The mdRNA molecule of claim 15 wherein the first strand is 15 to 25 nucleotides in length or 26 to 40 nucleotides in length.
17. The mdRNA molecule of claim 15 wherein the gap comprises from 1 to 10 unpaired nucleotides.
18. The mdRNA molecule of claim 15 wherein the mdRNA molecule comprises at least one 5-methyluridine, 2-thioribothymidine, or 2'-O-methyl-5- methyluridine.
AMENDED SHEET (ARTICLE 19)
19. The mdRNA molecule of claim 15 wherein the first strand is 19 to 23 nucleotides in length and is complementary to a human BCR-ABL nucleic acid sequence as set forth in any one of SEQ ID NOS:75-79, 83-90, and 1179-3152.
20. The mdRNA molecule of claim 15 wherein the first strand is 25 to 29 nucleotides in length and is complementary to a human BCR-ABL nucleic acid sequence as set forth in any one of SEQ ID NOS:75-79, 83-90, and 1179-3152.
21. A method for reducing the expression of a human BCR-ABL gene, comprising administering an mdRNA molecule according to any one of claims 1-20 to a cell expressing the human BCR-ABL gene, wherein the mdRNA molecule reduces the expression of the human BCR-ABL gene in the cell.
22. The method according to claim 21 wherein the cell is a human cell.
23. Use of an mdRNA as defined in any one of the preceding claims for the manufacture of a medicament for use in the therapy of a hyperproliferative or inflammatory disease.
24. A double-stranded ribonucleic acid (dsRNA) molecule that down regulates the expression of a human Breakpoint Cluster Region- Abelson Murine Leukemia Viral Oncogene homolog (BCR-ABL) mRNA, the dsRNA molecule comprising a first strand of 26 to 40 nucleotides in length that is complementary to a nucleic acid sequence as set forth in any one of SEQ ID NOS: 1158-1178 or SEQ ID NOS:1166-1178, and a second strand that is complementary to the first strand, and wherein upon annealing of the first strand and the second strand the dsRNA has a 3' overhang and a blunt end.
25. The dsRNA molecule of claim 24 wherein the first strand is from 27 to 35 nucleotides in length.
26. The dsRNA molecule of claim 24 wherein the dsRNA molecule comprises at least one 5-methyluridine, 2-thioribothymidine, or 2'-O-methyl-5- methyluridine.
27. The dsRNA molecule of claim 24 wherein the dsRNA molecule comprises at least one locked nucleic acid (LNA) molecule, deoxy nucleotide, G
AMENDED SHEET (ARTICLE 19) clamp, 2'-sugar modification, modified intemucleoside linkage, or any combination thereof.
28. The dsRNA molecule of claim 24 wherein the 3 '-overhang has from one to four nucleotides and is on the first strand.
29. The dsRNA molecule of claim 24 wherein the dsRNA molecule has a 5'-terminal end comprising a hydroxyl or a phosphate.
30. A dsRNA molecule that down regulates the expression of a human BCR-ABL mRNA, the dsRNA molecule comprising a first strand of 26 to 40 nucleotides in length that is complementary to a nucleic acid sequence as set forth in any one of SEQ ID NOS: 1158-1178 or SEQ ID NOS: 1166-1178, and wherein upon annealing of the first strand and the second strand the dsRNA has a 3' overhang and a blunt end, and wherein at least one pyrimidine of the dsRNA molecule comprises a pyrimidine nucleoside according to Formula I or II:
Figure imgf000007_0001
wherein:
R1 and R2 are each independently a -H, -OH, -OCH3, -OCH2OCH2CH3, -OCH2CH2OCH3, halogen, substituted or unsubstituted Ci-C10 alkyl, alkoxy, alkoxyalkyl, hydroxyalkyl, carboxyalkyl, alkylsulfonylamino, aminoalkyl, dialkylamino, alkylaminoalkyl, dialkylaminoalkyl, haloalkyl, trifluoromethyl, cycloalkyl, (cycloalkyl)alkyl, substituted or unsubstituted C2-C1O alkenyl, substituted or unsubstituted -O-allyl, -0-CH2CH=CH2, -0-CH=CHCH3, substituted or unsubstituted C2-C10 alkynyl, carbamoyl, carbamyl, carboxy, carbonylamino, substituted or unsubstituted aryl, substituted or unsubstituted aralkyl, -NH2, -NO2, -C≡N, or heterocyclo group,
R3 and R4 are each independently a hydroxyl, a protected hydroxyl, a phosphate, or an intemucleoside linking group, and R5 and R8 are each independently O or S.
31. The dsRNA molecule of claim 30 wherein the first strand is from 27 to 35 nucleotides in length.
32. The dsRNA molecule of claim 30 wherein at least one nucleoside is according to Formula I and in which R1 is methyl and R2 is -OH or -O-methyl.
33. The dsRNA molecule of claim 30 wherein at least one R2 is selected from the group consisting of 2'-0-(Ci-C5) alkyl, 2'-O-methyl, 2'-OCH2OCH2CH3, 2'-OCH2CH2OCH3, 2'-OaIIyI, and 2'-fluoro.
34. The dsRNA molecule of claim 30 wherein the dsRNA molecule comprises at least one 5-methyluridine, 2-thioribothymidine, or 2'-O-methyl-5- methyluridine.
35. The dsRNA molecule of claim 30 wherein the dsRNA molecule comprises at least one LNA, deoxy nucleotide, G clamp, 2'-sugar modification, modified internucleoside linkage, or any combination thereof.
36. The dsRNA molecule of claim 30, wherein the 3'-overhang has from one to four nucleotides and is on the first strand.
37. A method for reducing the expression of a human BCR-ABL gene, comprising administering a dsRNA molecule according to any one of claims 24-36 to a cell expressing the BCR-ABL gene, wherein the dsRNA molecule reduces the expression of the BCR-ABL gene in the cell.
38. The method according to claim 37 wherein the cell is a human cell.
39. Use of a dsRNA molecule as defined in any one of claims 24-38 for the manufacture of a medicament for use in the therapy of a hyperproliferative or inflammatory disease.
AMENDED SHEET (ARTICLE 19)
PCT/US2008/055378 2007-03-02 2008-02-28 Nucleic acid compounds for inhibiting bcr-abl gene expression and uses thereof WO2008109376B1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US93494007 true 2007-03-02 2007-03-02
US60/934,940 2007-03-02
US93493007 true 2007-03-16 2007-03-16
US60/934,930 2007-03-16
US94944307 true 2007-07-12 2007-07-12
US60/949,443 2007-07-12

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12552082 US20100105134A1 (en) 2007-03-02 2009-09-01 Nucleic acid compounds for inhibiting gene expression and uses thereof
US13327545 US20130011922A1 (en) 2007-03-02 2011-12-15 Nucleic acid compounds for inhibiting gene expression and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/055372 Continuation-In-Part WO2008109370A4 (en) 2007-03-02 2008-02-28 Nucleic acid compounds for inhibiting srd5a1 gene expression and uses thereof

Related Child Applications (3)

Application Number Title Priority Date Filing Date
PCT/US2008/055381 Continuation-In-Part WO2008109378A4 (en) 2007-03-02 2008-02-28 Nucleic acid compounds for inhibiting pdgfr gene expression and uses thereof
US12552082 Continuation-In-Part US20100105134A1 (en) 2007-03-01 2009-09-01 Nucleic acid compounds for inhibiting gene expression and uses thereof
AU2009212920A Division AU2009212920A8 (en) 2007-03-02 2009-09-01 Nucleic acid compounds for inhibiting gene expression and uses thereof

Publications (2)

Publication Number Publication Date
WO2008109376A1 true WO2008109376A1 (en) 2008-09-12
WO2008109376B1 true true WO2008109376B1 (en) 2008-11-20

Family

ID=39503875

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/055378 WO2008109376B1 (en) 2007-03-02 2008-02-28 Nucleic acid compounds for inhibiting bcr-abl gene expression and uses thereof

Country Status (1)

Country Link
WO (1) WO2008109376B1 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003070972A3 (en) * 2002-02-20 2004-06-03 Leonid Beigelman RNA INTERFERENCE MEDIATED INHIBITION OF CHROMOSOME TRANSLOCATION GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20050136437A1 (en) * 2003-08-25 2005-06-23 Nastech Pharmaceutical Company Inc. Nanoparticles for delivery of nucleic acids and stable double-stranded RNA
EP1814597A4 (en) * 2004-11-24 2009-04-22 Alnylam Pharmaceuticals Inc Rnai modulation of the bcr-abl fusion gene and uses thereof
EP1942943A2 (en) * 2005-11-04 2008-07-16 Nastech Pharmaceutical Company Inc. Peptide-dicer substrate rna conjugates as delivery vehicles for sirna

Also Published As

Publication number Publication date Type
WO2008109376A1 (en) 2008-09-12 application

Similar Documents

Publication Publication Date Title
Yates et al. The long and short of microRNA
Nykänen et al. ATP requirements and small interfering RNA structure in the RNA interference pathway
Guo et al. CELL-SELEX: Novel perspectives of aptamer-based therapeutics
WO2002055692A3 (en) Method for inhibiting the expression of a target gene and medicament for treating a tumor disease
Costa et al. MicroRNAs as molecular targets for cancer therapy: on the modulation of microRNA expression
Carthew A new RNA dimension to genome control
Shah et al. MicroRNAs as therapeutic targets in human cancers
WO2006066158A3 (en) Rnai modulation of mll-af4 and uses thereof
WO2009044899A1 (en) Nucleic acid capable of regulating the proliferation of cell
WO2004013280A3 (en) ALLELE-SPECIFIC siRNA-MEDIATED GENE SILENCING
WO2006083800A3 (en) Nucleic acid silencing of huntington's disease gene
WO2004015107A3 (en) Further novel forms of interfering rna molecules
WO2007109330A3 (en) S1p receptor modulating compounds
WO2005071080A3 (en) Modulation of glucocorticoid receptor expression
Agarwal et al. Furan based cyclic homo-oligopeptides bind G-quadruplex selectively and repress c-MYC transcription
WO2004007718A3 (en) Rna-interference by single-stranded rna molecules
WO2010013815A1 (en) Composition for inhibiting expression of target gene
WO2005028628A3 (en) Modulation of eif4e expression
WO2008073920A3 (en) Mir-21 regulated genes and pathways as targets for therapeutic intervention
WO2003070918A3 (en) Rna interference by modified short interfering nucleic acid
Nishiyama et al. pH-Dependence of the thermal stability of metallo-DNA duplexes containing ligand-type 5-hydroxyuracil nucleobases
WO2008091934A3 (en) Fructose 1, 6 bisphosphate - a novel anticonvulsant drug
WO2005105995A3 (en) RNA INTERFERENCE MEDIATED TREATMENT OF POLYGLUTAMINE (POLYQ) REPEAT EXPANSION DISEASES USING SHORT INTERFERING NUCLEIC ACID (siNA)
Mei et al. Optimizing System of SSR–PCR in Pinus radiata and Pinus tabulaeformis
WO2009120878A3 (en) Non-natural ribonucleotides, and methods of use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08731032

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct app. not ent. europ. phase

Ref document number: 08731032

Country of ref document: EP

Kind code of ref document: A1